1. Home
  2. CF vs BBIO Comparison

CF vs BBIO Comparison

Compare CF & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CF Industries Holdings Inc.

CF

CF Industries Holdings Inc.

SELL

Current Price

$120.90

Market Cap

17.6B

Sector

Industrials

ML Signal

SELL

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

SELL

Current Price

$66.47

Market Cap

15.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
CF
BBIO
Founded
1946
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
17.6B
15.9B
IPO Year
2005
2019

Fundamental Metrics

Financial Performance
Metric
CF
BBIO
Price
$120.90
$66.47
Analyst Decision
Hold
Strong Buy
Analyst Count
22
23
Target Price
★ $127.69
$108.27
AVG Volume (30 Days)
2.0M
★ 2.7M
Earning Date
11-04-2026
10-28-2026
Dividend Yield
★ 2.00%
N/A
EPS Growth
★ 33.09
N/A
EPS
★ 8.71
N/A
Revenue
★ $7,084,000,000.00
$502,076,000.00
Revenue This Year
$16.92
$105.95
Revenue Next Year
N/A
$63.81
P/E Ratio
$13.76
★ N/A
Revenue Growth
19.34
★ 126.26
52 Week Low
$75.42
$52.75
52 Week High
$141.96
$93.42

Technical Indicators

Market Signals
Indicator
CF
BBIO
Relative Strength Index (RSI) 52.42 45.05
Support Level $110.95 $63.22
Resistance Level $131.20 $69.47
Average True Range (ATR) 3.51 1.91
MACD 0.87 0.49
Stochastic Oscillator 89.81 71.48

Price Performance

Historical Comparison
CF
BBIO

About CF CF Industries Holdings Inc.

CF Industries is a leading producer and distributor of nitrogen, which is primarily used in fertilizers. The company operates nitrogen manufacturing plants primarily in North America. CF also produces nitrogen in the United Kingdom and holds a joint venture interest in a nitrogen production facility in Trinidad and Tobago. CF makes nitrogen primarily using low-cost US natural gas as its feedstock, making the company one of the lowest-cost nitrogen producers globally. It is also investing in carbon-free blue and green ammonia, which can be used as an alternative fuel to hydrogen or as a means to transport hydrogen.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: